… and reference eculizumab limits its potential to significantly improve treatment accessibility in … global phase III randomized controlled trial. EJHaem. 2025;6(2):e70020 … hemoglobinuria Jeremias S. FDA approves Epysqli as second Soliris biosimilar. The Center …

… the competitive landscape for GCA treatments is evolving. Just in … U.S. Food and Drug Administration (FDA) and the European Commission … from anti-C5 therapies (eculizumab or ravulizumab). The company … . After 24 weeks of treatment with Fabhalta, the Hb …

… 60. Historically, treatment strategies centered on corticosteroids … gMG Complement Inhibitors - Eculizumab (Soliris) and Ravulizumab (Ultomiris … Global Access: High drug costs and logistical … Increased collaboration between biotech firms and academic …

… the U.S. Food and Drug Administration (FDA) and Korea’s Ministry … adverse reaction observed with eculizumab treatment in clinical trials was headache, (occurred mostly … . 1 Soliris is a trademark of Alexion Pharmaceuticals 2 European Medicines Agency. Epysqli …

… needs not addressed by eculizumab or ravulizumab,” said Austin … those enrolled in previous trials, while offering an … history of cancer, unstable medical conditions including myocardial ischemia … Arm, Open Label Trial with Iptacopan Treatment for 24 Weeks, …

… of complement inhibitors such as Soliris (eculizumab) and Ultomiris (ravulizumab) has … renal replacement therapies, and lifelong medication usage make it a resource … affordable treatment that fits seamlessly into patients’ lives. Oral drugs like …

… such as satralizumab (Enspryng; Genentech), eculizumab (Soliris; Alexion), ravulizumab (Ultomiris; Alexion), … Amgen), may ultimately help inform treatment strategies for patients with NMOSD … she noted that the upcoming trial will compare efficacy of both …

… in a Phase IIa trial in order to … providing promising, innovative treatment options for patients with … eculizumab (brand name Soliris) (2). Eculizumab-aagh was approved by FDA … previously unmet medical needs (1). References 1. Teva Pharmaceutical Industries. …

Photo Credit: iStock.com/Pitju A rare CFI variant linked to severe neuroinflammation was found to be highly enriched in the Old Order Amish population.   A study published in June 2025 issue of Journal of Allergy and clinical Immunology highlighted …

… selling its proposed biosimilar eculizumab product, BEKEMV, in … ,810). In Alexion Pharmaceuticals, Inc v Amgen Canada … against Alexion’s eculizumab product SOLIRIS.  Eculizumab is a recombinant … SOLIRIS is the only medicine approved in Canada for the treatment …